Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus' SPN-820 failed to show significant improvement in depression severity in its Phase 2b study, with no difference from placebo. The safety profile of SPN-820 remained consistent with ...
The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback